Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Genitourinary (Prostate) Cancer

Type: Poster Session

Time: Saturday June 1, 1:15 PM to 4:15 PM

Location: Hall A

Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.

Sub-category:
Advanced Disease

Category:
Genitourinary (Prostate) Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
5032

Poster Board Number:
Poster Session (Board #144)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 5032)

Author(s): Edwin Lin, Andrew W Hahn, Guru Sonpavde, Michael B. Lilly, Roberto Nussenzveig, Elisa Ledet, Sumanta K. Pal, Petros Grivas, Thereasa A. Rich, Victoria M. Raymond, A. Oliver Sartor, Mark Yandell, Neeraj Agarwal; University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; University of Utah Hunstman Cancer Institute, Salt Lake City, UT; Dana-Farber Cancer Institute, Boston, MA; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Tulane University Cancer Center, New Orleans, LA; City of Hope National Medical Center, Duarte, CA; University of Washington, School of Medicine, Seattle, WA; Guardant Health, Redwood City, CA; Guardant Health, Inc., Redwood City, CA; Tulane Medical School, New Orleans, LA; University of Utah, Salt Lake City, UT; University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Abstract Disclosures

Abstract:

Background: All mPC patients eventually progress on current treatments and prognosis remains poor. In vitro models and small patient cohorts have shown that mPC progression is associated with increased MAPK/ERK signaling. However, in clinical mPC, the genomic alterations that cause aberrant MAPK/ERK signaling and their frequency are poorly defined. We hypothesize that profiling of genomic alterations in MAPK/ERK in a large cohort of heavily pretreated progressive mPC patients will provide a robust measure of importance, and reveal recurrent patterns of alteration. Given the large number of drugs that target MAPK/ERK, these may be incorporated into novel combinatorial treatments for mPC. Methods: 2,679 plasma samples from 2,309 men with mPC were assessed by a validated ctDNA NGS panel that sequences 73 clinically relevant cancer genes (Guardant360, Redwood City, CA) and profiles indels, amplifications, and fusions with high sensitivity and specificity. Genes were assigned to gene sets corresponding to biological pathways and molecular functional classes using the REACTOME database, followed by calculation of summary statistics. Interdependencies between genetic alterations at inter- and intra-gene set levels were discovered by a Bayesian network approach. Results: 56% of mPC samples harbored alterations in MAPK/ERK signaling genes. These included receptor tyrosine kinases (RTKs), MAP kinase cascade, and cell cycle control genes. Gene amplifications were the most frequent alterations in RTK, RAF, and cell cycle control genes, a novel finding. Bayesian network analysis revealed positive interdependencies between all MAPK/ERK genes. In RTK genes, co-amplifications were especially frequent between MET&EGFR and PDGFRA&KIT. Conclusions: In a large cohort of mPC patients, we show that MAPK/ERK gene alterations are present in over half of mPC patients. RTKs, BRAF, and CDK4/6 amplifications are among the most frequent events, display recurrent patterns of co-alteration, and are targetable by existing drugs. Future work to assess the biological and clinical significance of these recurrent patterns of alteration will pave the way for novel combinatorial treatments.

 
Other Abstracts in this Sub-Category:

 

1. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: LBA2 First Author: Christopher Sweeney
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

2. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 5000 First Author: Karim Fizazi
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

3. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).

Meeting: 2019 ASCO Annual Meeting Abstract No: 5001 First Author: Christian Carrie
Category: Genitourinary (Prostate) Cancer - Advanced Disease

 

More...